6:43 PM ET
Earnings Call
▶ Call
Definium Therapeutics Earnings Call: Key Takeaways
Definium Therapeutics reported positive Phase 3 results for DT120 in GAD and MDD, maintaining a strong $1.05 billion cash position to fund operations through 2030 while preparing for a 2027 NDA filing.
- Call
- Nov 9, 2026, 4:30 PM ET